Plain-English translation of NCT06930807 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
About 30% of early-stage lung cancer patients experience cancer recurrence after surgery, even when the surgery appears successful. This trial is testing whether a new approach using liquid biopsy—special blood tests that detect tiny traces of cancer DNA—can better predict which patients will relapse and guide personalized treatment plans. The goal is to help some patients avoid unnecessary chemotherapy while ensuring others get the treatment they need.
Current follow-up methods like routine chest X-rays and CT scans are not sensitive enough to catch early warning signs of recurrence. This new treatment approach could detect cancer signals much earlier through blood tests, allowing doctors to intervene sooner or spare patients from treatments they don't need.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either the new personalized approach or standard care. If you're in the new approach group, you'll have blood tests after surgery (and possibly after chemotherapy) to check for cancer DNA; if tests stay negative, you may skip additional chemotherapy. If tests show cancer signals, your care team will create a customized treatment plan for you. The standard care group receives typical follow-up chemotherapy and imaging. Both groups will be monitored closely over time with regular blood tests and imaging.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China